- done All payments are SSL encrypted
- done Full Refund if you haven't received your order
- done International shipping to the USA, UK and Europe
Lisoretic has an antihypertensive, diuretic effect.
Arterial hypertension (in patients for whom combination therapy is indicated).
1 tab. contains lisinopril 10 mg, hydrochlorothiazide 12.5 mg.
Excipients: calcium phosphate, mannitol, corn starch, pregelatinized starch, iron oxide red, iron oxide yellow, magnesium stearate, purified water.
Lisinopril, hydrochlorothiazide is marketed under different brands and generic names, and comes in different dosage forms:
|Brand name||Manufacturer||Country||Dosage form|
No customer reviews for the moment.
Dosage and Administration
To accept inside on 1 tab. Lisoretic 10 mg + 12.5 mg 1 time / day. If necessary, the dose can be increased to 1 table. Lisoretic 20 mg + 12.5 mg 1 time per day.
Doses for renal failure:
In patients with QA more than 30 and less than 80 ml / min, the drug can be used only after titration of the dose of the individual components of the drug. The recommended initial dose of lisinopril for uncomplicated renal failure is 5-10 mg.
Since the cardiovascular system: pronounced decrease in blood pressure, chest pain; rarely - orthostatic hypotension, tachycardia, bradycardia, the appearance of symptoms of heart failure, AV conduction disturbances, myocardial infarction.
From the digestive tract: nausea, vomiting, abdominal pain, dry mouth, diarrhea, dyspepsia, anorexia, change in taste, pancreatitis, hepatitis (hepatocellular and cholestatic), jaundice.
On the part of the skin: urticaria, increased sweating, photosensitivity, pruritus, hair loss.
From the nervous system: mood lability, impaired concentration, paresthesia, fatigue, drowsiness, jerking muscles of the limbs and lips; rarely - asthenic syndrome, confusion.
On the part of the respiratory system: dyspnea, bronchospasm, apnea.
From the hemopoietic system: leukopenia, thrombocytopenia, neutropenia, agranulocytosis, anemia (decrease in hemoglobin, hematocrit, erythrocytopenia).
Allergic reactions: angioedema of the face, extremities, lips, tongue, epiglottis and / or larynx, skin rash, itching, fever, vasculitis, positive reactions to antinuclear antibodies, increased ESR, eosinophilia.
From the genitourinary system: uremia, oliguria / anuria, impaired renal function, acute renal failure, reduced potency.
Laboratory indicators: hyperkalemia and / or hypokalemia, hyponatremia, hypomagnesemia, hypochloremia, hypercalcemia, hyperuricemia, hyperglycemia, increased levels of urea and creatinine in the blood plasma; hyperbilirubinemia, hypercholesterolemia, hypertriglyceridemia, reduced glucose tolerance, increased activity of hepatic transaminases, especially with a history of kidney disease, diabetes mellitus and renovascular hypertension.
Other: dry cough, arthralgia, arthritis, myalgia, fever, impaired fetal development, aggravation of gout.
- severe renal failure (CC less than 30 ml / min);
- angioneurotic edema (including a history of the use of ACE inhibitors);
- hemodialysis using high-flow membranes;
- precoma, hepatic coma;
- diabetes mellitus (severe forms);
- lactation period;
- age up to 18 years (efficacy and safety have not been established);
- hypersensitivity to the drug;
- hypersensitivity to other ACE inhibitors and sulfonamide derivatives.
With caution: aortic stenosis / hypertrophic cardiomyopathy, bilateral renal artery stenosis, arterial stenosis of the only kidney with progressive azotemia, condition after kidney transplantation, renal failure (CC more than 30 ml / min), primary hyperaldosteronism, arterial hypotension, bone marrow hypoplasia, ophthalmic, hypotension, bone marrow, hypothyroidism, hypothyroidism, hypothyroidism, hypothyroidism increased risk of arterial hypotension in patients on a low-salt or salt-free diet, conditions accompanied by a decrease in BCC (including diarrhea, vomiting), disease connective tissue (systemic lupus erythematosus, scleroderma), diabetes, gout, hyperuricemia, hyperkalemia, ischemic heart disease, cerebrovascular disease, severe chronic heart failure, liver failure, old age.
When applied simultaneously with potassium-sparing diuretics (spironolactone, triamterene, amiloride), potassium preparations, salt substitutes containing potassium, the risk of hyperkalemia increases, especially in patients with impaired renal function.
With simultaneous use with vasodilators, barbiturates, phenothiazines, tricyclic antidepressants, ethanol, the hypotensive effect is enhanced.
With simultaneous use with NSAIDs (indomethacin and others), estrogen decreases the antihypertensive effect of lisinopril.
With simultaneous use with lithium preparations, there is a slowdown in the elimination of lithium from the body (increased cardiotoxic and neurotoxic effects of lithium).
With simultaneous use with antacids and colestramin, absorption from the gastrointestinal tract is reduced.
The drug enhances the neurotoxicity of salicylates.
The drug reduces the effects of oral hypoglycemic agents, norepinephrine, epinephrine and anti-gout agents.
The drug enhances the effects (including side) of cardiac glycosides, the action of peripheral muscle relaxants.
The drug reduces the excretion of quinidine.
Reduces the effectiveness of oral contraceptives.
Pregnancy and Lactation
Application Lizoretika during pregnancy is contraindicated. When establishing pregnancy, the drug should be stopped as soon as possible. Acceptance of inhibitors in the II and III trimester of pregnancy has an adverse effect on the fetus (pronounced decrease in blood pressure, renal failure, hyperkalemia, cranial hypoplasia, fetal death are possible). Data on the negative effects of Lisoretic on the fetus in the case of use during the first trimester is not. For newborns and infants who have undergone intrauterine effects of ACE inhibitors, it is recommended to monitor for the timely detection of pronounced reduction in blood pressure, oliguria, hyperkalemia. For the period of drug treatment, it is necessary to cancel breastfeeding.
Most often, a pronounced decrease in blood pressure occurs with a decrease in BCC, caused by diuretic therapy, a decrease in the amount of salt in food, dialysis, diarrhea, or vomiting. In patients with chronic heart failure with simultaneous renal failure or without it, the development of symptomatic hypotension is possible. It is more often detected in patients with severe forms of heart failure, as a result of the use of large doses of diuretics, hyponatremia or impaired renal function. In such patients, treatment should begin under the strict supervision of a physician. Similar rules should be followed when prescribing patients with coronary artery disease, cerebrovascular insufficiency, in which a sharp decrease in blood pressure can lead to myocardial infarction or stroke.
Influence on ability to drive motor transport and control mechanisms:
During the period of treatment, patients should refrain from driving vehicles and engaging in potentially hazardous activities that require increased concentration and psychomotor speed, because dizziness is possible, especially at the beginning of the course of treatment.
Symptoms: pronounced decrease in blood pressure.
Treatment: artificial vomiting and / or gastric lavage, conducting symptomatic therapy aimed at correcting dehydration and disorders of water-salt balance. In case of arterial hypotension, an isotonic solution should be administered. It is necessary to control urea, creatinine and electrolytes in the blood serum, as well as diuresis.
- Brand name: Lysoretic
- Active ingredient: Lisinopril, hydrochlorothiazide
- Dosage form: Pills.
- Manufacturer: Ipka
- Country of Origin: India
- Spectrophotometric and HPTLC-densitometric determination of lisinopril and hydrochlorothiazide in binary mixtures
- A comparison of the effect of lisinopril and hydrochlorothiazide on electrolyte balance in essential hypertension
- A Case of Fatal Necrotizing Pancreatitis: Complication of Hydrochlorothiazide and Lisinopril Therapy
- Comparison of the AT1-receptor blocker, candesartan cilexetil, and the ACE inhibitor, lisinopril, in fixed combination with low dose hydrochlorothiazide in hypertensive patients
- Aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive type II diabetic individuals: effects on albumin excretion, endothelial function and inflammation in a double-blind, randomized clinical trial
- Effect of telmisartan/hydrochlorothiazide vs lisinopril/hydrochlorothiazide combination on ambulatory blood pressure and cognitive function in elderly hypertensive patients
- Aggressive antihypertensive strategies based on hydrochlorothiazide, candesartan or lisinopril decrease left ventricular mass and improve arterial compliance in patients with type II diabetes mellitus and hypertension
- Lisinopril versus lisinopril plus hydrochlorothiazide in essential hypertension
- Comparison of long-term hemodynamic effects at rest and during exercise of lisinopril plus sodium restriction versus hydrochlorothiazide in essential hypertension
- Effects of hydrochlorothiazide, amiloride, and lisinopril on the metabolic, hemodynamic, and electrocardiographs responses to increased plasma epinephrine
- Hydrochlorothiazide increases plasma or tissue angiotensin-converting enzyme-inhibitor drug levels in rats with myocardial infarction: Differential effects on lisinopril and zofenopril
- Comparison of the hemodynamic and metabolic effects of low-dose hydrochlorothiazide and lisinopril treatment in obese patients with high blood pressure
- C27 - Cardiac, renal and vascular effects of a combined treatment with the ACE inhibitor lisinopril and the diuretic hydrochlorothiazide in SHR
- Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension
- Efficacy and Tolerability of Delapril Plus Indapamide Versus Lisinopril Plus Hydrochlorothiazide Combination Treatments in Mild to Moderate Hypertension: A Multicenter, Randomized Clinical Study
- Metabolic effects of lisinopril versus hydrochlorothiazide plus amiloride in essential hypertension
- Lisinopril versus hydrochlorothiazide in mild-to-moderate systolic/diastolic or isolated systolic hypertension in the elderly
- Lisinopril and hydrochlorothiazide/amiloride: A comparative study in the treatment of patients with mild-to-moderate hypertension
- H2 Effect of lisinopril (L), hydrochlorothiazide (H) and dipper/non-dipper status on 24-hour ambulatory blood pressure (ABP) in obese hypertensives
- H23 Efficacy of lisinopril Vs hydrochlorothiazide in obese hypertensive patients
- E056 Combination of candesartan cilexetil/hydrochlorothiazide 8/12.5 mg has a similar antihypertensive effect and is better tolerated than lisinopril/hydrochlorothiazide 10/12.5 mg
- Amlodipine/hydrochlorothiazide/lisinopril overdose
- Stability-Indicating LC Method for the Simultaneous Determination of Lisinopril and Hydrochlorothiazide